Federal health regulators announced Wednesday they have given the green light to a new treatment for a rare inherited disease developed by Denali Therapeutics.
This regulatory approval represents a milestone achievement for the pharmaceutical company, marking their inaugural FDA clearance in the United States.
Following the announcement, Denali’s stock price climbed 4.2% to reach $21.86 per share.
The newly approved medication, which will be sold under the brand name Avlayah, serves as an enzyme replacement treatment designed to combat Hunter syndrome. This uncommon inherited condition causes harmful accumulation of specific sugar compounds throughout the brain and other organs.
Hunter syndrome develops when patients lack sufficient amounts of the enzyme iduronate-2-sulfatase, leaving their bodies unable to properly process large sugar molecules known as glycosaminoglycans.
